Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
NEW YORK & AACHEN, Germany, April 02, 2024--Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection devic
Source: yahoo.com
